While drug-makers have agreed to an $80 billion in fees and hospitals agreed to a $155 billion cut in Medicare reimbursements over the next decade as part of health reform, device-makers did not cooperate with the finance committee and the committee chose the payment level without negotiating with the industry.
Now the device industry is engaged in an extensive campaign to have the fee removed from the legislation.
Read USA Today’s feature on the orthopedic device industry.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
